Adipose-derived mesenchymal stem cells ameliorate hyperglycemia through regulating hepatic glucose metabolism in type 2 diabetic rats

Infusion of adipose‑derived mesenchymal stem cells inhibits skeletal muscle mitsugumin 53 elevation and thereby alleviates insulin resistance in type 2 diabetic rats

“…A recent study indicated a novel mechanism by which MSCs alleviated insulin resistance, which involved the regulation of M2 macrophage polarization and promotion of interleukin-6 production in adipose tissue (33). Another study indicated that MSCs improved hyperglycemia by regulating hepatic glucose metabolism in an AMP-activated protein kinase signaling pathway-dependent manner (17). However, in the peripheral insulin target tissues, skeletal muscle accounts for ~70-90% of insulin-stimulated glucose disposal, which serves an important role in the modulation of insulin resistance (23).…”

“…Adipose-derived MSC isolation, culture and identification. Adipose-derived MSCs were isolated and purified from immature rats as described previously (17,19). Briefly, rats were anesthetized with pentobarbital sodium intraperitoneally (60 mg/kg) and sacrificed by cervical dislocation; adipose tissue isolated from the groin was digested using 0.05% trypsin and 0.1% collagen I.…”

“…Following filtration and centrifugation at 600 x g for 10 min at room temperature, cells were cultured in low-glucose Dulbecco's modified Eagle's medium (Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) supplemented with 10% fetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.), penicillin (80 U/ml) and streptomycin (0.2 mg/ml) at 37˚C in an atmosphere of 5% CO 2 and a relative humidity of ~100%. MSCs were identified as previously described (17,19). In order to perform surface immunophenotype analysis, third passage (P3) MSCs were used for flow cytometry.…”

“…These properties of MSCs make them excellent candidates for diabetes management. To date, numerous studies on diabetic animal models have demonstrated that infusion of MSCs ameliorates hyperglycemia (14)(15)(16)(17). In addition, the majority of registered clinical trials on MSC-treated type 1 and/or type 2 diabetes in phase I/II have indicated that MSC administration exerts promising therapeutic effects in diabetic volunteers (18).…”

Basic and clinical study of stem cell treatment for diabetes mellitus in China

“…比例, 而通过小干扰RNA抑制MSCs中IL-6表达, 显著 抑制脂肪组织中M2型巨噬细胞极化, 从而很大程度上 抑制MSCs减轻脂肪组织胰岛素抵抗的效应. 脂肪来源 间充质干细胞(adipose stromal cells, ASCs)通过激 活AMPK磷酸化促进肝脏肝糖原合成并抑制肝糖输 出而改善肝脏胰岛素抵抗 [17] ; 此外UC-MSCs还可通 过下调2型糖尿病大鼠肝脏和脂肪组织中慢性炎症 小体NLRP3的表达, 改善肝脏和脂肪组织的慢性炎 症, 激活PI3K-AKT的表达, 改善大鼠的胰岛素抵抗 [18] . 上述研究结果为干细胞治疗糖尿病奠定了新的理论 基础.…”